Navigation Links
New Treatment For Obstructive Sleep Apnea Now Available In Canada
Date:11/19/2012

nt has been used effectively in the United States since 2008 and in clinical studies, Provent Therapy improved quality of sleep while it reduced apnea (breathing disruptions), daytime sleepiness and snoring. Importantly, Provent is easy to use, portable and discreet for use at home or when travelling."

CPAP is the primary treatment of OSA and is extremely effective if worn as directed. However, up to half of all patients are not compliant with CPAP therapy due to the cumbersome nature of the treatment. Provent Therapy was developed to help patients who cannot tolerate CPAP therapy and will benefit from the small, non-invasive and effective technology, which Provent Therapy provides.

In patients with OSA the airway collapses during sleep when the muscles that hold it open relax. People with this disorder stop breathing during sleep---in some cases hundreds of times each night---usually for periods of ten seconds or longer. OSA can lead to fatigue, early morning headaches, irritability, lack of concentration, and contributes to depression, learning and memory difficulties, and sexual dysfunction. Importantly, recent studies have shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, stroke and diabetes.

"As we look at global market opportunities for Provent Therapy, Canada fits directly into our corporate strategy, which is to target markets where three factors come together: high prevalence of OSA, acceptance of innovative therapies, and importantly, a need for new therapeutic options that address low patient compliance," stated Peter Wyles, President and Chief Executive Officer of Ventus Medical. "With ioSleep and their extensive experience in sleep disorder treatment and diagnosis, we are pleased to present Provent Therapy as a new treatment to manage this troubling condition."

About Provent® Sleep Apnea Therapy

Provent is a proprietary medical device used for the treatment of O
'/>"/>

SOURCE Ventus Medical
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 A decade-long ... in Helmholtz Zentrum München, Germany , ... autoantibodies and the risk of developing type 1 diabetes ... preventions for the disease. The study, "Seroconversion to Multiple ... Children," was published today in The Journal of ...
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
... GREENWOOD VILLAGE, Colo., June 16, 2011 Ampio Pharmaceuticals, ... discovers and develops new uses for previously approved drugs ... is set to join the U.S. broad-market Russell 3000 ... U.S. and global equity indices on June 24, according ...
Cached Medicine Technology:Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4Ampio Pharmaceuticals Set to Join Russell 3000 Index 2Ampio Pharmaceuticals Set to Join Russell 3000 Index 3
(Date:6/19/2013)... June 19 online edition of the journal Nature ... University of California, San Diego School of Medicine visually ... cardiac regeneration occurs in zebrafish after cardiac ventricular injury. ... in the heart are more plastic, or capable of ... More importantly, the research reveals a novel potential source ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... significant disparities between minority and white clients in ... Moreover, these disparities vary widely from state to ... most states there,s something amiss," says Stephan Arndt, ... are strong racial and ethnic disparities for people ... programs successfully, and those disparities are something we ...
(Date:6/19/2013)... In early April, senior leaders from medical, law ... to discuss one question: how can first responders improve ... The preliminary results of this discussion are now available ... Hartford Consensus ," a concept paper published in the ... Trauma and Acute Care Surgery , official publication ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on at ... take two, Mayo Clinic researchers say. Antibiotics, antidepressants ... study found. Twenty percent of patients are on ... findings, published online in the journal Mayo ... and video of Dr. Jennifer St. Sauver talking ...
Breaking Medicine News(10 mins):Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
... science and progress of integrative medicine in the ... convene the "Summit on Integrative Medicine and the ... D.C. The summit will bring together distinguished researchers, ... the vision, challenges, evidence base, and opportunities for ...
... Control Weight Permanently , MIDLAND, Mich., Jan. 27 ... is the challenge. With this Health Enhancement Systems ... Healthy Weight for Life ( ... gain control of their weight -- and improve their health ...
... the fight against,oral cancer is now being offered by Barotz ... http://www.barotzdental.com , determines a,person,s risk for oral cancer disease in ... Americans are diagnosed with oral cancer each year. While,easy ... death rate,because it is routinely discovered late in its development," ...
... of the European Heart Rhythm Association (EHRA), is today ... More than 4,000 participants are expected to attend this ... and sudden cardiac death. , EHRA is a registered ... mission is to reduce the impact of cardiac arrhythmias ...
... Meanwhile, U.S. officials say illnesses linked to tainted peanut ... 27 (HealthDay News) -- The Georgia facility that produced ... nationwide salmonella outbreak has a history of health-inspection violations, ... officials reported Monday that the outbreak, which has now ...
... Forever" Solution , , DALLAS, Jan. 27 ... it,s swept under the rug as a nuisance. However, ... an indicator of a serious health problem called obstructive sleep ... of Plano is announcing a dental approach to end snoring ...
Cached Medicine News:Health News:IOM gathers health care leaders for summit on integrative medicine 2Health News:Thousands Look Better, Feel Better, and Have More Energy Because of NutriSum 2Health News:Barotz Dental Offers Free Online Oral Cancer Risk Assessment 2Health News:EUROPACE 2009 2Health News:Salmonella Outbreak Site Has History of Health Violations: Report 2Health News:Spouses of the Lone Star State Rejoice As Snoring Is DOA 2
For determination of triglycerides in serum or plasma. For Hitachi 704 / 911. Available with calibrator: Trucal U and also with controls: Trulab N, Trulab P, Trulab L....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
For the quantitative determination of triglycerides in serum. Linearity: 1000 mg/dl....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Medicine Products: